降脂治疗需转变观念
Shifting views on lipid lowering therapy
摘要
Harlan Krumholz和Rodney Hayward认为预防心脏病学应当尽可能地基于能够改善患者结局的策略，而非仅关注生化标志物。
出处
《英国医学杂志中文版》
2010年第6期340-342,共3页
The BMJ Chinese Edition
参考文献25
-
1Bridges to Excellence. Coronary artery, disease care link. http:// bridgestoexcellence, org/Content/ContentDisplay, aspx ? ContentlD - 190.
-
2Jackevicius CA, Tu JV, Ross IS, Ko DT, Krumholz HM. Use of ezetimibe in the United States and Cmmda. N Engl J Med 2008;358:1819-28.
-
3Pettypiece S. Schering-Plough, Merck probed over adds for Vytorin (Update 2). Bloomberg 2008 Jan 16. www. bloomberg, com/apps/news? pid = 20601087&sid = a7OG9SnYNm7w&refer = home.
-
4National Heart, Lung, and Blood Institute. Detection, evaluation, and treatment of high blood cholesterol in adults ( adult treatment panel III). 2001. www. nhlbi, nih. gov/guidelines/cholesterol/atp iii. htm.
-
5Lee TH, Cleeman JI, Grundy SM, Gillett C, Pasternak RC, Seidman J, et al. Clinical goals and performance measures for cholesterol management in secondary prevention of coronary heart disease. JAMA 2000 ;283:94-8.
-
6Steinberg D, Glass CK, Witztum JL. Evidence mandating earlier and more aggressive treatment of hypercholesterolemia. Circulation 2008;118:672-7.
-
7Report of the national cholesterol education program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Arch Intern Med 1988 : 148,36-69.
-
8LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005 ;352 : 1425-35.
-
9Hayward RA, Hofer TP, Vijan S. Narrative review: lack of evidence for recomroended low-density lipoprotein treatment targets: a solvable problem. Ann Intem Med 2006;145:520-30.
-
10Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007 ;357:2109-22.
-
1张翔（编译）.病毒唑可使SARS患者结局恶化[J].传染病网络动态,2005(9):6-6.
-
2影响生长代谢机能药物[J].国外科技资料目录（医药卫生）,1998(8):198-199.
-
3潘云芳,张厚亮.缺血修饰白蛋白研究进展及临床应用[J].医学综述,2008,14(10):1444-1446. 被引量：3
-
4杨光,张燕.骨质疏松骨代谢标志物研究进展[J].广州医药,2006,37(1):8-10. 被引量：12
-
5孙诚,王桥生,叶珩,朱高峰,陈纯波,胡北,霍家聪,黄瑞英,曾红科.高渗盐水对大鼠脑水肿及脑损伤标志物的影响[J].中国急救医学,2012,32(7):619-622. 被引量：2
-
6刘洁,李伟,董明纲.新一代骨转换标志物研究现状[J].中国临床医学,2006,13(1):102-104. 被引量：6
-
7毛琴琴,王晓明.联合检测hs-CRP、cTnI和心肌酶谱在诊断儿科感染性疾病的应用[J].临床血液学杂志（输血与检验）,2014,27(6):1018-1020. 被引量：2
-
8梁永会,李琼,王晓红.心脏生化标志物联合检测在非ST段抬高急性冠脉综合征预后评价中的意义[J].海南医学,2013,24(3):323-326. 被引量：7
-
9王琳,熊为国,郭晓宁,陈新.脑利钠肽的生理特性及其重组脑利钠肽在急性心力衰竭治疗中的应用[J].中华心律失常学杂志,2006,10(1):77-78. 被引量：16
-
10崔丹丹,王晓良,彭英.帕金森病脑脊液和血液生物标志物的研究进展[J].中国药理学与毒理学杂志,2016,30(12):1254-1263. 被引量：5
